Helmsley Charitable Trust Grants $4.7m to Fund Life-Saving Technology to Confront Cardiac Threat from COVID-19

Helmsley Charitable Trust reports $4,711,481 in funding will be distributed across five upper-midwestern states to pay for 367 LUCAS mechanical CPR devices to be deployed to hospitals caring for patients during the pandemic and beyond.

“These devices are vital because we don’t want frontline healthcare workers to choose between trying to save a patient or risking exposure to themselves and others to the Coronavirus,” said Walter Panzirer, a trustee for the Helmsley Charitable Trust. “LUCAS has been a proven, effective tool in saving lives during cardiac arrest, and having more of them available during this pandemic will save even more lives, including those of the doctors, nurses and other healthcare workers.”

Research has shown cardiac damage in as many as 1 in 5 COVID-19 patients, leading to heart failure and death even among those who show no signs of respiratory distress. Among patients who recover, many could have long-term effects from such heart damage.

The rise in cardiac complications caused by COVID-19 exposes both patients and healthcare workers to greater risk, as hands-on CPR can be needed for extended periods. Mechanical CPR has been adopted by emergency medical responders and many hospitals around the globe.

The Helmsley Charitable Trust is partnering with medical facilities in South Dakota, North Dakota, Montana, Wyoming, and Nebraska to ensure the devices are in place before the peak of COVID-19 hits. The devices will remain in place after the pandemic as part of the hospitals’ cardiac system of care.

“We were able to go from concept to delivery of the devices in two weeks, and that’s been an incredible effort of teamwork with the manufacturer and the hospitals,” said Panzirer.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version